GenoMed's Treatment for West Nile Virus Encephalitis Is Published; 100% Successful So Far for General Population Including the Elderly
FOR IMMEDIATE RELEASE
Contact:
Dr. David Moskowitz
GenoMed, Inc.
tel. 314-652-0500
July 19, 2004--St. Louis-- GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management(tm) company, announced today the publication of its initial case series of 8 patients with West Nile virus encephalitis in a special pharmacogenomics issue of "Current Topics in Medicinal Chemistry," a peer reviewed journal.
Since the article was written, the Company has treated 4 more patients with documented West Nile virus encephalitis. GenoMed's record currently stands at 11-1. All 11 successes have been in patients with an intact immune system. The single failure came in an immunosuppressed patient with chronic leukemia last summer. GenoMed's treatment is therefore restricted to the general population, and not offered to immunosuppressed patients.
People treated in the throes of acute WNV encephalitis respond within 24 hours on average, whereas people treated months after their encephalitis are taking months to respond.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Publication of our case series in a peer-reviewed medical journal now establishes our treatment as the 'state of the art.' We use already existing, safe medications. We're offering our treatment for free this summer to see whether our 100% response rate will hold up. We would like people who are worried about West Nile virus to think of GenoMed."
Anyone can enroll in GenoMed's trial at any time of day or night by clicking on the "West Nile trial" link at genomedics.com, or going directly to
b2i.us
About GenoMed
GenoMed's goal is to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. As a Next Generation Disease Management(tm) company, GenoMed is already marketing its treatments to prevent kidney dialysis due to diabetes and high blood pressure, and to delay the progression of emphysema.
. |
